Published in Hepatitis Weekly, October 16th, 2000
The trial is being conducted at the Beth Israel Deaconess Medical Center in Boston, Massachusetts. Dr. Keith Stuart, Harvard Medical School, and Beth Israel Deaconess Medical Center in Boston, observed, "Hepatocellular carcinoma is one of the leading causes of worldwide cancer deaths, and yet there is no good chemotherapy treatment for this disease. We developed this trial because irofulven has a novel mechanism of action and has shown early signs of activity in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly